



Therapeutic strategy for Novel COVID-19

Laila M. Montaser

Department of Clinical Pathology, Faculty of Medicine, menoufia University, Egypt

Abstract:

Statement of the Problem: As plentiful are conscious the novel COVID-19 is gripping quickly all over the globe. Scientists and clinicians anywhere are functioning as fast as they can to recognize how this novel virus works and to test to discover therapies and progress vaccines. While there are no specific treatments for COVID-19 at the moment, there is reason to test if blood-derived plasma rich in growth factors (PRGF) could help mitigate the damaging inflammation associated with COVID-19 pneumonia. Based on the positive results in animal and research studies, PRGF were already in clinical trials for the treatment of a number of conditions, even before the emergence of COVID-19. There are so many stories in the news about convalescent plasma and COVID-19 cases? The purpose: is to propose PRGF from recovered patients as a therapy for new COVID-19 patients. Methodology & Theoretical Orientation: I present a method standardized and optimized in my lab proposed as a therapy established on the thought that antibodies progressed by recuperated cases may prop the immune system of novel sick persons. The antibodies included in the plasma of blood possess the power to link to and equalize the virus that responsible for COVID-19. Findings: I expect to use the antibodies created by recovered cases as a succeeded therapy for novel sick persons, with the target of consolidation their immune systems and decreasing the riskiness of symptoms connected with the new virus. Conclusion & Significance: There is a hope that my proposed therapy could shed light on a promising remedy. The treatment might be an ideal choice to be used or combined with other immune modulating agents. I would pick up novel science from such disaster. Recommendations: I recommend the use of PRGF as a treatment to novel COVID-19. Such strategy is merit attempting.

Biography:

Laila M. Montaser, MD is Professor of Clinical Pathology. She is Chair, of Stem Cell, Regenerative Medicine, Nanotechnology and Tissue Engineering (SRNT) Research Group. She serves as the Head, Founder Leader of Clinical Pathology Department, Faculty of Medicine, Menoufia University. She is the nominator of Council of Menoufia University to TWAS prize in Medical Sciences and to award of Nano Science Research Excellence. She gained 4 Awards: - Gold Medal of perfect and



Certificate of Excellence for the best pupil in Alexandria Governorate from Egyptian Feast of Science. - Medal of Merit from Egyptian Medical Syndicate in 1986, 1998, and 2002. She supervised more than 44 M. Sc. theses and 13 Doctorate theses. She has made Faculty of Medicine a hub at Menoufia University. She is uniquely trained and situated and has a philosophy on how to manage research specifically with Stem Cell, Regenerative Medicine, Nano medicine and Tissue Engineering.

Recent Publications:

1. Montaser L (2020). Editorial; A Therapeutic Approach from Lab to Clinic in the Domain of the Disease Caused by the Novel Coronavirus from the Perspective of an Egyptian Scientist. *CPQ Medicine*; 8(6): 1-7.
2. Montaser L (2020). Keynote speech: Innovative outlook for COVID-19. Presented at 13rd Int. Conf. on Pharmaceutical Chemistry 22 may 2020 Webinar, Paris, France.
3. Montaser L (2020). Keynote speech: Innovative prospective strategy for therapy of COVID-19 pneumonia. Presented at 33rd Int. Conf. on Nanoscience and Nanotech April 27, 2020 Webinar, London, UK.
4. Montaser L, Eid T, Helwa M, Mesregah M (2017). Application of platelet-rich plasma preparation rich in growth factors in knee osteoarthritis. *Men Med J* 2017 July; 30 (1): 139-146.
5. Montaser L, Abbassy H, Fawzy S (2016). Articular cartilage tissue engineering with plasma-rich in growth factors and stem cells with Nano scaffolds. *Proc. SPIE* 2016, 9930, 99300V, San Diego, CA, USA.

Webinar on Novel COVID-19 and its impact on the Healthcare System | July 15, 2020 | Dubai, UAE

Citation: Laila M. Montaser, Therapeutic strategy for Novel COVID-19, Novel Covid-19, 2020, July 15, Dubai, UAE